0001144204-19-044429.txt : 20190912
0001144204-19-044429.hdr.sgml : 20190912
20190912164301
ACCESSION NUMBER: 0001144204-19-044429
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190912
FILED AS OF DATE: 20190912
DATE AS OF CHANGE: 20190912
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191090776
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
3
1
tv529301_3.xml
OWNERSHIP DOCUMENT
X0206
3
2019-09-12
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001055951
ORBIMED ADVISORS LLC
C/O SPRINGWORKS THERAPEUTICS, INC.
100 WASHINGTON BLVD.
STAMFORD
CT
06902
0
0
1
0
Series A Convertible Preferred Stock
Common Stock
6078103
I
By OrbiMed Capital GP VI LLC
Series B Convertible Preferred Stock
Common Stock
1053204
I
By OrbiMed Capital GP VI LLC
Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
/s/ Douglas Coon
2019-09-12